Skip to main content
Equibles
MNKD logo

MNKD · Mannkind Corp · Webcasts, Transcripts & Audio

Track MNKD — free

Use MNKD with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MNKD.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$3.56 +0.13 (+3.64%) Q2 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$1.10B
Shares
321.54M
Volume · Oct 29 399.46K Avg daily vol (3M) 4.26M

Mannkind Corp Webcasts

Earnings calls, investor updates, investor days and conferences for Mannkind Corp (MNKD), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP → Add these events to your calendar (.ics)
Conference
Investor event
2026-10-20
Mannkind Corp (MNKD) October 20, 2026 Conference
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-15
Mannkind Corp (MNKD) September 15, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-05
Mannkind Corp (MNKD) Q2 2026 Earnings Call Transcript
Confident tone Regulatory pathway for IPF program (Mankind 201) Furosix ReadyFlow approval Revenue growth and diversification
Revenue
$109.37M
▲ 42.9% YoY
Diluted EPS
$-0.06
Gross margin
86.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-03
Mannkind Corp (MNKD) June 3, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-06
Mannkind Corp (MNKD) Q1 2026 Earnings Call Transcript
Confident tone FURO6 auto-injector United Therapeutics / Tyvaso DPI MNKD-201 / nintedanib DPI
Revenue
$90.17M
▲ 15.1% YoY
Diluted EPS
$-0.05
▼ 225% YoY
Gross margin
91.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Mannkind Corp (MNKD) Q4 2025 Earnings Call Transcript
Confident tone Afrezza growth and pediatric opportunity Furoscix performance and integration Pipeline and FDKP technology platform
Revenue
$111.95M*
▲ 45.8% YoY
Gross margin
87.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-05
Mannkind Corp (MNKD) Q3 2025 Earnings Call Transcript
Confident tone Record Q3 Revenue and Commercial Momentum Afrezza Pediatric Label Expansion Margin and Cost Considerations
Revenue
$82.13M
▲ 17.2% YoY
Diluted EPS
$0.03
▼ 25% YoY
Gross margin
94.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-06
Mannkind Corp (MNKD) Q2 2025 Earnings Call Transcript
Confident tone Afrezza / Endocrine (incl. pediatric) Nintedanib DPI / INFLO Phase II Blackstone financing & balance sheet
Revenue
$76.53M
▲ 5.7% YoY
Diluted EPS
$0.00
Gross margin
94.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Mannkind Corp (MNKD) Q1 2025 Earnings Call Transcript
Confident tone Endocrine/Afrezza commercial performance Inhaled nintedanib (MNKD-201) for IPF Pediatric and label expansion of Afrezza
Revenue
$78.35M
▲ 18.2% YoY
Diluted EPS
$0.04
▲ 0% YoY
Gross margin
95.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-26
Mannkind Corp (MNKD) Q4 2024 Earnings Call Transcript
Confident tone Afrezza pediatric opportunity Diabetes / Endocrine business growth Tyvaso DPI collaboration / United Therapeutics
Revenue
$76.78M*
▲ 31.3% YoY
Gross margin
93.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Mannkind Corp (MNKD) Q3 2024 Earnings Call Transcript
Confident tone Afrezza commercial performance and diabetes Nintedanib DPI (MNKD-201) for IPF Clofazamine Inhalation (MNKD-101) Phase 3 in NTM
Revenue
$70.08M
▲ 36.7% YoY
Diluted EPS
$0.04
▲ 300% YoY
Gross margin
95.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-07
Mannkind Corp (MNKD) Q2 2024 Earnings Call Transcript
Confident tone Afrezza Commercial Growth INHALE-3 Trial & Endocrine Pipeline Clofazimine Inhalation Suspension (NTM)
Revenue
$72.39M
▲ 48.9% YoY
Diluted EPS
$-0.01
Gross margin
92.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Mannkind Corp (MNKD) Q1 2024 Earnings Call Transcript
Confident tone Endocrine (Afrezza, V-Go) and diabetes pipeline Tyvaso DPI royalties and collaboration Financial performance and balance sheet
Revenue
$66.26M
▲ 63.1% YoY
Diluted EPS
$0.04
Gross margin
94.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-27
Mannkind Corp (MNKD) Q4 2023 Earnings Call Transcript
Confident tone Tyvaso DPI royalty and monetization Pipeline (MNKD-101 clofazimine and MNKD-201) INHALE-1 and INHALE-3 clinical readouts
Revenue
$58.47M*
▲ 62.2% YoY
Gross margin
89.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Mannkind Corp (MNKD) Q3 2023 Earnings Call Transcript
Revenue
$51.25M
▲ 56.1% YoY
Diluted EPS
$0.01
Gross margin
92.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-07
Mannkind Corp (MNKD) Q2 2023 Earnings Call Transcript
Revenue
$48.61M
▲ 157.3% YoY
Diluted EPS
$-0.02
Gross margin
89.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Mannkind Corp (MNKD) Q1 2023 Earnings Call Transcript
Revenue
$40.63M
▲ 238.8% YoY
Diluted EPS
$-0.04
Gross margin
86.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-23
Mannkind Corp (MNKD) Q4 2022 Earnings Call Transcript
Revenue
$36.06M*
▲ 188.1% YoY
Gross margin
88.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-08
Mannkind Corp (MNKD) Q3 2022 Earnings Call Transcript
Revenue
$32.83M
▲ 47.8% YoY
Diluted EPS
$-0.06
Gross margin
84.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-09
Mannkind Corp (MNKD) Q2 2022 Earnings Call Transcript
Revenue
$18.89M
▼ 18.8% YoY
Diluted EPS
$-0.11
Gross margin
75.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Mannkind Corp (MNKD) Q1 2022 Earnings Call Transcript
Revenue
$11.99M
▼ 31.2% YoY
Diluted EPS
$-0.10
Gross margin
81.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-24
Mannkind Corp (MNKD) Q4 2021 Earnings Call Transcript
Revenue
$12.52M*
▼ 32.1% YoY
Gross margin
65.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-09
Mannkind Corp (MNKD) Q3 2021 Earnings Call Transcript
Revenue
$22.21M
▲ 44.7% YoY
Diluted EPS
$-0.02
Gross margin
82.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-11
Mannkind Corp (MNKD) Q2 2021 Earnings Call Transcript
Revenue
$23.28M
▲ 54% YoY
Diluted EPS
$-0.14
Gross margin
81.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-12
Mannkind Corp (MNKD) Q1 2021 Earnings Call Transcript
Revenue
$17.44M
▲ 7.4% YoY
Gross margin
75.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-02-25
Mannkind Corp (MNKD) Q4 2020 Earnings Call Transcript
Revenue
$18.44M*
▲ 15.3% YoY
Gross margin
80.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-04
Mannkind Corp (MNKD) Q3 2020 Earnings Call Transcript
Revenue
$15.35M
▲ 5.2% YoY
Gross margin
76.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-05
Mannkind Corp (MNKD) Q2 2020 Earnings Call Transcript
Revenue
$15.11M
▲ 0.7% YoY
Gross margin
75.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-06
Mannkind Corp (MNKD) Q1 2020 Earnings Call Transcript
Revenue
$16.23M
▼ 7% YoY
Gross margin
74.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-02-25
Mannkind Corp (MNKD) Q4 2019 Earnings Call
Revenue
$15.99M
▼ 0.2% YoY
Gross margin
71.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–30 of 30 webcasts
Key facts CIK 899460 CUSIP 56400P706 13F (30d) 56 filings 54 filers Visit website Investor relations